Evotec (OTCMKTS:EVTCY) Upgraded to Hold by Zacks Investment Research

Evotec (OTCMKTS:EVTCY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Separately, Deutsche Bank upgraded Evotec from a “hold” rating to a “buy” rating in a report on Wednesday, August 21st.

Shares of OTCMKTS EVTCY remained flat at $$42.71 during trading hours on Monday. The company has a quick ratio of 1.33, a current ratio of 1.36 and a debt-to-equity ratio of 0.36. The firm has a market cap of $3.18 billion, a PE ratio of 32.36 and a beta of 1.21. The stock’s 50 day moving average price is $43.95 and its 200-day moving average price is $50.64. Evotec has a 12 month low of $35.57 and a 12 month high of $59.50.

Evotec (OTCMKTS:EVTCY) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.26). The firm had revenue of $116.02 million during the quarter. Evotec had a net margin of 19.00% and a return on equity of 15.24%. Sell-side analysts expect that Evotec will post 0.52 earnings per share for the current year.

About Evotec

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.

Further Reading: How does a security become overbought?

Get a free copy of the Zacks research report on Evotec (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.